Opinion|Videos|November 19, 2026

Bridging Therapy Before CAR T-Cell Therapy in DLBCL

In this segment, Dr. Caron A. Jacobson discusses the role of bridging therapy for patients with diffuse large B-cell lymphoma (DLBCL) awaiting CAR T-cell infusion.

In this segment, Dr. Caron A. Jacobson discusses the role of bridging therapy for patients with diffuse large B-cell lymphoma (DLBCL) awaiting CAR T-cell infusion. She explains that observational studies have reported differing associations between bridging therapy and outcomes, partly reflecting differences in patient populations and disease characteristics. Patients who receive bridging therapy may have more aggressive disease, greater tumor burden, elevated lactate dehydrogenase (LDH), or increased inflammatory markers, which can also influence outcomes following CAR T-cell therapy. Dr. Jacobson describes considering bridging treatment for patients with lymphoma-related symptoms or a high risk of progression during the interval before infusion. Treatment selection depends on prior therapies, response history, current symptoms, and laboratory findings. She also emphasizes coordination between the CAR T-cell center and community oncologist to schedule bridging therapy around leukapheresis, lymphodepleting chemotherapy, and infusion, while promptly communicating unexpected toxicities that could affect treatment timing. The discussion highlights individualized treatment decisions and ongoing communication to support safe, timely care.


Related to this article